Floatz logo

Futibatinib

FGFR2 Amplification

Taiho Oncology, Inc.Small moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the FGFR2 Amplification cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Taiho Oncology, Inc.
Phase 2CCC
Lirafugratinib
Elevar Therapeutics
Phase 1/2CCC

Same molecule, other indications

Futibatinib is also rated in:

Advanced or Metastatic Solid TumorDormant
CCC
Indicative ·
54 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →